As we previously mentioned, it is essential to develop new selective and effective inhibitors of PTP1B to treat PTP1B-related diseases, such as T2DM, obesity, lymphoma, and breast cancer [35,43,44,45,46,47,48,49]. Here, PTPN1 is linked to obesity disorder.